A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation Duchenne muscular dystrophy

被引：0
|
作者：
Riebling, P. [1 ]
Kong, R. [2 ]
O'Mara, E. [1 ]
Luo, X. [1 ]
Trifillis, P. [1 ]
Ong, T. [1 ]
机构：
[1] PTC Therapeut Inc, South Plainfield, NJ USA
[2] PTC Therapeut, South Plainfield, NJ USA
来源：
NEUROMUSCULAR DISORDERS | 2017年 / 27卷
关键词：
D O I：
10.1016/j.nmd.2017.06.446
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.406
引用
收藏
页码：S218 / S218
页数：1
相关论文
共 50 条
  • [1] A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged ≥2 to <5 years with nonsense mutation Duchenne muscular dystrophy
    Kong, R.
    O'Mara, E.
    Luo, X.
    Trifillis, P.
    Werner, C.
    McIntosh, J.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S12 - S13
  • [2] Duchenne Muscular Dystrophy: Ataluren in Nonsense Mutation
    Manych, Matthias
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2018, 86 (04)
  • [3] Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystrophy
    Campbell, Craig
    Shieh, Perry
    Sejersen, Thomas
    Luo, Xiaohui
    Elfring, Gary
    Kroger, Hans
    Riebling, Peter
    Ong, Tuyen
    Spiegel, Robert
    Peltz, Stuart
    Wong, Brenda
    NEUROLOGY, 2016, 86
  • [4] ATALUREN IN PATIENTS AGED ≥ 2 TO < 5 YEARS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD): 28-WEEK RESULTS FROM A PHASE 2 STUDY
    Tian, Cuixia
    Kong, Robert
    O'Mara, Edward
    Schilling, Traci
    Trifillis, Panayiota
    McIntosh, Joseph
    Ben Renfroe, J.
    MUSCLE & NERVE, 2018, 58 : S15 - S15
  • [5] Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy
    McDonald, Craig
    Bushby, Katharine
    Tulinius, Mar
    Finkel, Richard
    Topaloglu, Haluk
    Day, John
    Flanigan, Kevin
    Lowes, Linda
    Eagle, Michelle
    Luo, Xiaohui
    Elfring, Gary
    Kroger, Hans
    Riebling, Peter
    Ong, Tuyen
    Spiegel, Robert
    Peltz, Stuart
    Kirschner, Jan
    NEUROLOGY, 2016, 86
  • [6] Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutation Duchenne muscular dystrophy
    Riebling, P.
    O'Mara, E.
    Luo, X.
    Trifillis, P.
    Ong, T.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S218 - S218
  • [7] DESIGN OF A PHASE 3 TRIAL TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY
    Trifillis, Panayiota
    Schilling, Traci
    O'Mara, Edward
    McIntosh, Joseph
    MUSCLE & NERVE, 2018, 58 : S59 - S59
  • [8] Design of a Phase 3 Trial to Evaluate the Long-Term Efficacy and Safety of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
    Trifillis, Panayiota
    Riebling, Peter
    O'Mara, Edward
    Luo, Xiaohui
    McIntosh, Joseph
    NEUROLOGY, 2018, 90
  • [9] Meta-analyses of ataluren in patients with nonsense mutation Duchenne muscular dystrophy
    Muntoni, F.
    Mercuri, E.
    Luo, X.
    Elfring, G.
    Werner, C.
    Trifillis, R.
    Peltz, S. W.
    McDonald, C. M.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S12 - S12
  • [10] Two Phase 2 Trials to Assess Production of Dystrophin in Patients with Nonsense Mutation Duchenne Muscular Dystrophy Receiving Ataluren
    Nelson, S.
    Penematsa, V
    Chou, C.
    Trifillis, P.
    Bibbiani, F.
    McIntosh, J.
    ANNALS OF NEUROLOGY, 2019, 86 : S127 - S127
12345